Skye Bioscience, Inc.
SKYE
$2.08
-$0.045-2.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.48% | 15.16% | -96.18% | 310.28% | 119.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.14% | 161.02% | 42.37% | 195.67% | 98.45% |
| Operating Income | -91.14% | -161.02% | -42.37% | -195.67% | -98.45% |
| Income Before Tax | -121.25% | -120.51% | 84.37% | -154.02% | 2.90% |
| Income Tax Expenses | 0.00% | -- | -- | 125.00% | -- |
| Earnings from Continuing Operations | -121.20% | -120.51% | 84.37% | -153.99% | 2.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.20% | -120.51% | 84.37% | -153.99% | 2.86% |
| EBIT | -91.14% | -161.02% | -42.37% | -195.67% | -98.45% |
| EBITDA | -89.11% | -158.53% | -41.65% | -198.18% | -99.70% |
| EPS Basic | -56.16% | 31.57% | 96.83% | 74.47% | 86.93% |
| Normalized Basic EPS | -27.18% | 35.26% | 76.55% | 73.73% | 73.19% |
| EPS Diluted | -55.56% | 31.57% | 96.83% | 74.47% | 86.88% |
| Normalized Diluted EPS | -27.18% | 35.26% | 76.55% | 73.73% | 73.19% |
| Average Basic Shares Outstanding | 41.61% | 222.28% | 392.60% | 895.04% | 643.18% |
| Average Diluted Shares Outstanding | 41.61% | 222.28% | 392.60% | 895.04% | 643.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |